Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPT-302 + Aflibercept in Persistent DME
NCT03397264Phase 2Completed
- Sponsor
- Opthea Limited
- Start
- Jan 2018
- Primary completion
- Mar 2020
- Modality
- Antibody Fragments, Fc-Fusion Proteins
- Countries
- 4
01
Overview
A Phase 2 trial of sozinibercept in diabetic macular edema (DME), sponsored by Opthea Limited. Started Jan 2018; status: completed.
02
Drugs
sozinibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT03397264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03397264.